These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 37908957)

  • 21. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.
    Heerspink HJL; Kosiborod M; Inzucchi SE; Cherney DZI
    Kidney Int; 2018 Jul; 94(1):26-39. PubMed ID: 29735306
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sodium-Glucose Cotransporter-2 inhibitors are potential therapeutic agents for treatment of non-diabetic heart failure patients.
    Nakagawa Y; Kuwahara K
    J Cardiol; 2020 Aug; 76(2):123-131. PubMed ID: 32340780
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence.
    Davidson JA
    Postgrad Med; 2019 May; 131(4):251-260. PubMed ID: 30929540
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of SGLT2 Inhibitors on Atherosclerosis: Lessons from Cardiovascular Clinical Outcomes in Type 2 Diabetic Patients and Basic Researches.
    Xu J; Hirai T; Koya D; Kitada M
    J Clin Med; 2021 Dec; 11(1):. PubMed ID: 35011882
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pleiotropic effects of SGLT2 inhibitors beyond the effect on glycemic control.
    Satoh H
    Diabetol Int; 2018 Oct; 9(4):212-214. PubMed ID: 30603370
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SGLT2 inhibitors reduce infarct size in reperfused ischemic heart and improve cardiac function during ischemic episodes in preclinical models.
    Andreadou I; Bell RM; Bøtker HE; Zuurbier CJ
    Biochim Biophys Acta Mol Basis Dis; 2020 Jul; 1866(7):165770. PubMed ID: 32194159
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SGLT2 Inhibitors and the Diabetic Kidney.
    Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
    Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Cardiovascular and renal protection with SGLT2 inhibitors: from EMPA-REG OUTCOME to VERTIS CV].
    Scheen AJ
    Rev Med Suisse; 2020 Aug; 16(703):1483-1488. PubMed ID: 32852168
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of sodium-glucose cotransporter 2 inhibitors with cardiovascular outcome and safety events: A meta-analysis of randomized controlled clinical trials.
    Gong C; Shen SC; Zhang K; Zhou L; Shen JJ; Zhao JY; Ding SG; Ma LK; Gao H
    Front Cardiovasc Med; 2022; 9():926979. PubMed ID: 36312269
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
    Lingvay I
    Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure.
    Galli M; D'Amario D; Sofia C; Vaccarella M; Crea F; Aspromonte N
    Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1273-1285. PubMed ID: 30472914
    [No Abstract]   [Full Text] [Related]  

  • 32. Cardio-renal benefits of sodium-glucose co-transporter 2 inhibitors in heart failure with reduced ejection fraction: mechanisms and clinical evidence.
    Aguilar-Gallardo JS; Correa A; Contreras JP
    Eur Heart J Cardiovasc Pharmacother; 2022 May; 8(3):311-321. PubMed ID: 34264341
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emerging concepts in heart failure management and treatment: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction.
    De Lorenzi AB; Kaplinsky E; Zambrano MR; Chaume LT; Rosas JM
    Drugs Context; 2023; 12():. PubMed ID: 36660013
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lessons from a pre-specified meta-analysis of sodium-glucose cotransporter-2 (SGLT2) inhibitors in heart failure: Time for new clinical recommendations.
    Kotit S
    Glob Cardiol Sci Pract; 2023 May; 2023(2):e202314. PubMed ID: 37351098
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SGLT2 Inhibitors: Emerging Roles in the Protection Against Cardiovascular and Kidney Disease Among Diabetic Patients.
    Vasquez-Rios G; Nadkarni GN
    Int J Nephrol Renovasc Dis; 2020; 13():281-296. PubMed ID: 33149657
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Closing the knowledge gap on cardiovascular disease in type 2 diabetes: the EMPA-REG OUTCOME trial and beyond.
    Oral EA
    Drugs Context; 2016; 5():212299. PubMed ID: 27648101
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SGLT2 inhibitors in heart failure with reduced ejection fraction.
    Das US; Paul A; Banerjee S
    Egypt Heart J; 2021 Oct; 73(1):93. PubMed ID: 34693498
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Benefits of Sodium-Glucose Cotransporter 2 Inhibitors and the Mechanisms Underlying Their Cardiovascular Effects.
    Kubota Y; Shimizu W
    JACC Asia; 2022 Jun; 2(3):287-293. PubMed ID: 36338417
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Utilization Rates of SGLT2 Inhibitors Among Patients With Type 2 Diabetes, Heart Failure, and Atherosclerotic Cardiovascular Disease: Insights From the Department of Veterans Affairs.
    Hussain A; Ramsey D; Lee M; Mahtta D; Khan MS; Nambi V; Ballantyne CM; Petersen LA; Walker AD; Kayani WT; Butler J; Slipczuk L; Rogers JG; Bozkurt B; Navaneethan SD; Virani SS
    JACC Heart Fail; 2023 Aug; 11(8 Pt 1):933-942. PubMed ID: 37204363
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus.
    Pancholia AK
    Indian Heart J; 2018; 70(6):915-921. PubMed ID: 30580866
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.